AL008 / Alector - LARVOL DELTA

IBI397 or Combination Therapies in Patients With Advanced Malignancies (clinicaltrials.gov) - P1a/1b | N=0 | Withdrawn | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | N=30 ➔ 0 | Trial completion date: Dec 2023 ➔ Aug 2023 | Recruiting ➔ Withdrawn

Combination therapy • Enrollment change • Metastases • Trial completion date • Trial withdrawal • Hematological Malignancies • Oncology

AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors. (PubMed, J Immunol) - "AL008 also significantly potentiated the effects of T cell checkpoint blockade with anti-programmed death ligand-1 in syngeneic tumor models. This dual and specific mechanism of AL008, to our knowledge, provides a novel therapeutic strategy for targeting myeloid cells for immune activation."

Journal • Oncology • CD86 • SIRPA

IBI397 or Combination Therapies in Patients With Advanced Malignancies (clinicaltrials.gov) - P1a/1b | N=30 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Hematological Malignancies • Oncology • Solid Tumor

Alector Reports Fourth Quarter and Full Year 2021 Financial Results (StockHouse) - "A Phase 1 clinical study of treatment with AL008 in patients with advanced solid tumors is expected to begin in the first half of 2022 in China."

New P1 trial • Oncology • Solid Tumor

IBI397 or Its Combination Therapies in Patients With Advanced Malignancies (clinicaltrials.gov) - P1a/1b | N=30 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Combination therapy • New P1 trial • Hematological Malignancies • Oncology • Solid Tumor

Alector Provides 2021 Corporate Portfolio Update (GlobeNewswire) - "In the next 18 months, AL008, a novel, investigational, antibody product candidate with a dual mechanism of action that combines inhibition of the CD47-SIRP-alpha (SIRPα) pathway, with stimulation of activating Fc receptors to yield a potential best-in-class product will enter into clinical development...In the next 18 months, Alector plans to initiate the clinical development of ADP009, a first-in-class multi-Siglec inhibitor that works to enhance the innate and adaptive immune system response by blocking a critical glycan checkpoint pathway that drives immune inhibition. This product candidate is initially being developed for oncology indications..."

New trial • Oncology